Home › FDA Approves Mercks LIPTRUZET (ezetimibe and atorvastatin), a New Product That Can Help Powerfully Lower LDL Cholesterol
 

Keywords :   


FDA Approves Mercks LIPTRUZET (ezetimibe and atorvastatin), a New Product That Can Help Powerfully Lower LDL Cholesterol

2013-05-03 21:06:15| Merck.com - Research & Development News

Dateline City:  WHITEHOUSE STATION, N.J. LIPTRUZET Approved for Patients with Primary or Mixed Hyperlipidemia, as an Adjunct to Diet When Diet Alone Is Not Enough Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved LIPTRUZET(ezetimibe and atorvastatin) tablets for the treatment of elevated low-density lipoprotein (LDL) cholesterol in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet when diet alone is not enough. Language:  English Ticker Slug:  Ticker: MRK Exchange: NYSE read more

Tags: product lower cholesterol fda

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
16.05Eastern North Pacific Tropical Weather Outlook
16.05Atlantic Tropical Weather Outlook
16.05The man who turned his dead father into a chatbot
16.05Firms leaving UK 'not a crisis' says stock market boss
15.05Exploring the future of agriculture
15.05American, Mexican, and Canadian cattle producers sign joint statement
15.05Attitudes EWG Verified Skincare Line Oceanly Expands with SPF Offerings
15.05Sherwin-Williams Packaging Coatings Expands Non-BPA Coatings Production in Europe
More »